JENA, Germany--(BUSINESS WIRE)--InflaRx announced today the successful closing of its round B financing by completing the second of two tranches within this round. All current investors as well as new private investors participated in this financing round B reaching an investment volume in the double digit million Euro space. The proceeds of this round will enable clinical phase II development of IFX-1, the first-in-class anti complement lead drug monoclonal antibody, in different acute inflammatory indications. In addition, the company explained that this funding shall foster pre-clinical development of IFX-2 as follow on antibody for the treatment of selected chronic inflammatory diseases and enable the development of a new bedside complement activation test in collaboration with a diagnostic partner.
Help employers find you! Check out all the jobs and post your resume.
